•
Sinopharm China National Biotech Group Co., Ltd (CNBG) has announced partnerships with two foreign medical equipment firms to set up joint ventures (JVs) with majority stakes controlled by the state-owned company. This strategic move aims to enhance Sinopharm’s capabilities in the medical equipment sector. Radiotherapy and Imaging Joint VenturesSinopharm’s subsidiary,…
•
China-based biotech BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) held a ceremony to mark the “topping off” of construction at its new biologics manufacturing and R&D facility in Hopewell, New Jersey. The last piece of structural steel was laid at the site, signaling that construction is now expected to be…
•
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into a partnership with China-based China Resource Medicine Commercial Holdings Ltd to jointly promote the anti-influenza drug Xofluza (baloxavir marboxil) in China. Under the agreement, Roche will continue to handle channel promotion for the drug in major hospitals, while CR Medicine Commercial…
•
China-based Jacobio Pharma (HKG: 1167) has announced a clinical partnership with Merck, Sharp & Dohme Inc. (NYSE: MRK) to assess the clinical effects of Jacobio’s CD73 monoclonal antibody (mAb) JAB-BX102 combined with Merck’s PD-1 inhibitor Keytruda (pembrolizumab) in advanced solid tumors. No financial details were disclosed in the partnership agreement.…
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary Evive Biotech Ltd’s F-652 has been cleared to start a Phase II clinical trial for a new indication by China’s National Medical Products Administration (NMPA). The trial will assess F-652 as a treatment for alcoholic hepatitis (AH). Mechanism…
•
Germany-based mRNA specialist BioNTech SE (NASDAQ: BNTX) has unveiled a licensing deal and collaboration with US-based biotech OncoC4, securing global development and commercialization rights to OncoC4’s anti-CTLA-4 antibody ONC-392. Under the terms of the agreement, BioNTech will pay OncoC4 USD 200 million upfront, with further undisclosed development and commercial milestone…
•
Beijing-based second-generation sequencing technology platform Cygnus Bio has reportedly raised “hundreds of millions” of renminbi in a Series C+ financing round. The round was led by Source Code Capital, with contributions from CCB Private Equity Investment, E-town Capital, Founder H Fund, and Lotus Lake Capital. The funds will be used…
•
Shanghai-based tumor immunotherapy developer L&L Biopharma Co., Ltd has announced the completion of a Series B financing round, led by Hongfeng Venture. Additional investors included Oriental Wisdom Capital, Zhongchuang Yongjian (Ningbo) Venture Capital, and existing investor Qiao Jing Capital. The funds will be directed towards Phase I clinical studies for…
•
Beijing-based cell and gene therapy (CGT) developer T&L Biotechnology Co., Ltd has reportedly raised RMB 100 million (USD 14.53 million) in a Series A financing round. The round was led by Harvest Capital and Fortune Capital, with participation from Zhiheng (Yantai) Entrepreneurship Service Center. The funds will be used to…
•
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its novel biologic product BIO-008. This marks a significant milestone in the development of the company’s innovative therapeutic biologic. Development and IndicationsBIO-008 is a monoclonal antibody…
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that a market approval filing for SHR8028, an anti-inflammatory and immunomodulatory agent under development to treat dry eye, has been accepted for review by the National Medical Products Administration (NMPA) in China. Clinical Study and ResultsThe filing is based on…
•
China-based LBX Pharmacy has entered into a partnership with US-based Gilead Sciences, Inc (NASDAQ: GILD). The collaboration will focus on channel building, chronic disease compliance, member and private domain traffic management, and access to innovative drugs. Gilead aims to leverage LBX’s extensive network of over 10,000 drugstores, chronic disease and…
•
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced that it has received Emergency Use Authorization (EUA) from Mongolia for its ReCOV, a recombinant COVID-19 vaccine co-developed by the Chinese Academy of Sciences. This authorization marks a significant milestone in the global distribution and accessibility of the…
•
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) released its 2022 financial report, recording revenues of RMB 39.355 billion (USD 5.72 billion), a 71.8% increase year-on-year (YOY). Net profits also grew significantly, reaching RMB 8.814 billion (USD 1.28 billion), up 72.9% YOY. This marks a substantial milestone in the…
•
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing for its subsidiary Shandong Boan Biotechnology Co., Ltd’s BA1102, a biosimilar version of Amgen’s (NASDAQ: AMGN) Xgeva (denosumab), has been accepted for review by the Center for Drug Evaluation (CDE). Indications and Market ContextDenosumab is a monoclonal…
•
German pharmaceutical giant Bayer AG (ETR: BAYN) has announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its drug Nubeqa (darolutamide). The drug, which was previously approved for use in non-metastatic castration-resistant prostate cancer (nmCRPC) in February 2021, can now be used to…
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) announced in a stock exchange statement that the National Medical Products Administration (NMPA) has declined to issue a market approval for plinabulin, a potential first-in-class GEF-H1-targeted small-molecule drug in-licensed from US-based BeyondSpring Inc. (NASDAQ: BYSI). Hengrui was seeking approval for the drug’s use…
•
SciClone Pharmaceuticals Inc (HKG: 6600) has announced that a clinical trial filing for its Vaborem (meropenem vaborbactam), a new antibacterial drug, has been approved by the National Medical Products Administration (NMPA). This approval allows the drug to enter a Phase III clinical study in China. Study Objectives and DesignThe Phase…
•
US-based Janssen Pharmaceutical reportedly decided to withdraw Carvykti (ciltacabtagene autoleucel; cilta-cel) from the UK market last week. The BCMA-targeted chimeric antigen receptor (CAR) T cell therapy, which is under development globally by Janssen in partnership with China-based Legend Biotech (NASDAQ: LEGN), was being assessed by the UK’s National Institute of…
•
US-based Leap Therapeutics Inc. (NASDAQ: LPTX) announced last week that China-based BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) had declined to exercise its option to take up development and commercial rights in Asia for DKN-01, Leap’s anti-Dickkopf-1 (DKK1) monoclonal antibody (mAb). Despite this decision, the two companies will continue…